What are the properties of CBG in supplements?

CBG - References & External links

CBG (Cannabigerol)

TBS Ingredient ID (TBSI ID):	IS953B20
Name
CBG Synonyms:
Chemical Formula:
C21H32O2
Molecular Formula:
Classification Type	Identifier
PubChem CID: U.S. National Library of Medicine (PubChem)	5315659
InChI Key: International Chemical Identifier hash (InChIKey) computed from chemical structure using the International Union of Pure and Applied Chemistry (IUPAC) standard	QXACEHWTBCFNSA-SFQUDFHCSA-N
CAS: A proprietary registry number assigned by the Chemical Abstracts Service (CAS) division of the American Chemical Society (ACS)	25654-31-3
NIST: The National Institute of Standards and Technology (NIST)	25654-31-3
ChemIDplus: United States National Library of Medicine - TOXNET (Toxicology Data Network).	25654-31-3
KEGG: Kyoto Encyclopedia of Genes and Genomes (KEGG)	C20219
ChEMBL: An open data resource of binding, functional and ADMET bioactivity data (ChEMBL)	CHEMBL497318
UNII: FDA Substance Registration System - Unique Ingredient Identifier	J1K406072N

The references to scientific articles about CBG are not meant to imply that any products treat, cure, or diagnose any disease or human condition. We encourage our audience to do their own research beyond the resources we have provided so your decision is as educated as possible.

• The general properties of CBG:
  • CITTI, Cinzia; et al. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). Journal of Pharmaceutical and Biomedical Analysis, 2018, 149: 532-540. PMID:29182999
  • NACHNANI, Rahul; RAUP-KONSAVAGE, Wesley M.; VRANA, Kent E. The Pharmacological Case For Cannabigerol (CBG). Journal of Pharmacology and Experimental Therapeutics, 2020, Nov 9: JPET-MR-2020-000340. PMID:33168643
  • SZCZESNIAK, Anna-Maria; et al. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure. Journal of ocular pharmacology and therapeutics, 2011, 27.5: 427-435. PMID:21770780
  • NAVARRO, Gemma; et al. Cannabigerol Action at Cannabinoid CB 1 and CB 2 Receptors and at CB 1-CB 2 Heteroreceptor Complexes. Frontiers in pharmacology, 2018, 9: 632. PMID:29977202
  • NAVARRO, Gemma; et al. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB 1, CB 2 and CB 1/CB 2 heteromer receptors. Pharmacological Research, 2020, 159: 104940. PMID:32470563
    Conclusion: Results here reported and the recent elucidation of the three-dimensional structure of CB1 and CB2 receptors help understanding the mechanism of action that might be protective and the molecular drug-receptor interactions underlying biased signaling.
  • GRANJA, Aitor G.; et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. Journal of Neuroimmune Pharmacology, 2012, 7.4: 1002-1016. PMID:22971837
  • TURNER, Sarah E.; et al. Molecular Pharmacology of Phytocannabinoids. Progress in the chemistry of organic natural products, 2017, 103: 61-101. PMID:28120231
  • STONE, Nicole L.; et al. A systematic review of minor phytocannabinoids with promising neuroprotective potential. British Journal of Pharmacology, 2020, 177.19: 4330-4352. PMID:32608035
  • ROSS, Samir A.; et al. Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L. Phytochemical Analysis: An International Journal of Plant Chemical and Biochemical Techniques, 2005, 16.1: 45-48. PMID:15688956
• The properties of CBG boosting Brain / Mental Clarity:
  • CASCIO, Maria Grazia; et al. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British journal of pharmacology, 2010, 159.1: 129-141. PMID:20002104